{"filing":{"accession_number":"0000105770-26-000097","cik":"0000105770","ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"wst-20260723.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/wst-20260723.htm"},"events":[{"id":19812,"run_id":17828,"accession_number":"0000105770-26-000097","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"West Pharmaceutical Services issued a press release on July 23, 2026 announcing second-quarter 2026 financial results, including net sales of $872.3 million (up 13.8%), diluted EPS of $2.15 (up 18.1%), and adjusted-diluted EPS of $2.37 (up 28.8%), along with raised full-year 2026 guidance for net sales and EPS.","company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19006,"accession_number":"0000105770-26-000097","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"West Pharmaceutical Services issued a press release on July 23, 2026 announcing second-quarter 2026 financial results, including net sales of $872.3 million (up 13.8%), diluted EPS of $2.15 (up 18.1%), and adjusted-diluted EPS of $2.37 (up 28.8%). The company also raised full-year 2026 net sales and EPS guidance. This is a standard quarterly earnings release with detailed financial statements and forward guidance, clearly falling under Item 2.02 disclosure of results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:15:40.438508+00:00","company_name":"","ticker":null,"filing_date":""},{"id":19007,"accession_number":"0000105770-26-000097","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The Item 7.01 disclosure incorporates by reference Item 2.02 (Results of Operations and Financial Condition) and attaches the company's earnings release (Exhibit 99.1) announcing second-quarter 2026 financial results. The release reports net sales of $872.3 million (up 13.8%), diluted EPS of $2.15 (up 18.1%), and raises full-year 2026 guidance for both net sales and adjusted EPS. This is a standard earnings release disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:15:40.438508+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19006,"accession_number":"0000105770-26-000097","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"West Pharmaceutical Services issued a press release on July 23, 2026 announcing second-quarter 2026 financial results, including net sales of $872.3 million (up 13.8%), diluted EPS of $2.15 (up 18.1%), and adjusted-diluted EPS of $2.37 (up 28.8%). The company also raised full-year 2026 net sales and EPS guidance. This is a standard quarterly earnings release with detailed financial statements and forward guidance, clearly falling under Item 2.02 disclosure of results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:15:40.438508+00:00","company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","filing_date":"2026-07-23"},{"id":19007,"accession_number":"0000105770-26-000097","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The Item 7.01 disclosure incorporates by reference Item 2.02 (Results of Operations and Financial Condition) and attaches the company's earnings release (Exhibit 99.1) announcing second-quarter 2026 financial results. The release reports net sales of $872.3 million (up 13.8%), diluted EPS of $2.15 (up 18.1%), and raises full-year 2026 guidance for both net sales and adjusted EPS. This is a standard earnings release disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:15:40.438508+00:00","company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","filing_date":"2026-07-23"}]}